Prevalence and 24‐month recovery of olfactory dysfunction in COVID‐19 patients: A multicentre prospective study

Journal of Internal Medicine, Год журнала: 2022, Номер 293(1), С. 82 - 90

Опубликована: Авг. 24, 2022

Abstract Objective To investigate the prevalence and recovery of olfactory dysfunction (OD) in COVID‐19 patients 24 months after infection. Methods From 22 March 2020 to 5 June 2022, 251 were followed three European medical centres. Olfactory function was assessed with subjective patient‐reported outcome questionnaires odour identification tests at baseline, 6, 12, 18 postinfection. The predictive values epidemiological clinical data investigated multivariate analysis. Results One hundred seventy‐one completed evaluations. test revealed that 123 (50.8%) had OD baseline. persistent psychophysical abnormalities post‐COVID‐19 24.2%, 17.9%, 5.8% 2.9%, respectively ( p = 0.001). Parosmia occurred 40 (23.4%) lasted 60 ± 119 days. At 2 years, 51 (29.8%) self reported their olfaction unnormalised. Older better evaluations baseline < 0.001) but those lower scores end follow‐up. more frequently young patients. training significantly associated higher Sniffin’ Sticks postinfection (r s 0.678; Conclusion Two years post‐COVID‐19, 29.8% OD, only 2.9% abnormal

Язык: Английский

---

Prevalence of olfactory dysfunction in D614G, alpha, delta and omicron waves: a psychophysical case-control study

Rhinology Journal, Год журнала: 2022, Номер 0(0), С. 0 - 0

Опубликована: Окт. 22, 2022

Background: The purpose of this study was to compare the prevalence olfactory dysfunction (OD) at different stages COVID-19 pandemic by evaluating subjects diagnosed with SARS-CoV-2 infection during Omicron wave psychophysical tests and comparing results those obtained from patients infected D614G, Alpha Delta waves a control group. Methodology: included adult infection. Depending on time diagnosis, were divided into four groups: D614G; Alpha, variant groups. A group uninfected individuals used as control. All underwent evaluation function Connecticut Chemosensory Clinical Research Center test (D614G groups) or extended version Sniffin'Sticks (Delta, groups). Results: 372 cases (134 D614G group, 118 32 in 88 group) recruited evaluated within 10 days infection, alongside 80 controls. Patients self-reported loss 72.4% 75.4% 65.6% 18.1% Psychophysical revealed OD: 80.6%, 83.0%, 36.3% respectively. differences between groups not statistically significant. demonstrated significantly lower OD than other variants but still higher Conclusions: During less prevalent periods. One-third have reduced wave. Our should be considered caution VOC has been determined certainty.

Язык: Английский

---

Mechanisms of COVID‐19‐associated olfactory dysfunction

Neuropathology and Applied Neurobiology, Год журнала: 2024, Номер 50(2)

Опубликована: Фев. 28, 2024

Olfactory dysfunction is one of the most common symptoms COVID-19. In first 2 years pandemic, it was frequently reported, although its incidence has significantly decreased with emergence Omicron variant, which since become dominant viral strain. Nevertheless, many patients continue to suffer from persistent dysosmia and dysgeusia, making COVID-19-associated olfactory an ongoing health concern. The proposed pathogenic mechanisms are complex likely multifactorial. While evidence suggests that infection sustentacular cells associated mucosal inflammation may be culprit acute, transient smell loss, alterations in other components system (e.g., receptor neuron dysfunction, bulb injury cortex) lead persistent, long-term dysfunction. This review aims provide a comprehensive summary epidemiology, clinical manifestations current understanding

Язык: Английский

---

Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction

Life, Год журнала: 2022, Номер 12(10), С. 1483 - 1483

Опубликована: Сен. 24, 2022

Persistent olfactory dysfunction is a major concern post-COVID-19, affecting up to 5% of all patients. Different therapeutic options, including mometasone nasal spray, have been recommended, only some which validated for post-COVID-19 dysfunction. In this study we psychophysically assessed the effect intranasally applied furoate on recovery olfaction. The spray was with long applicator so that cleft could be reached effectively. After had confirmed using Sniffin' Sticks, patients were randomly assigned two different treatment arms: group (n = 40) underwent training and intranasal administration twice daily, whereas control 46) performed only. duration three months, psychophysical testing olfaction repeated Sticks. We found no benefit an additional topical compared alone. These results confirm previous studies based patients' subjective self-ratings. Our findings are in contrast current recommendations management might adapted accordingly.

Язык: Английский

---

Pathophysiology of SARS-CoV-2 Infection of Nasal Respiratory and Olfactory Epithelia and Its Clinical Impact

Current Allergy and Asthma Reports, Год журнала: 2023, Номер 23(2), С. 121 - 131

Опубликована: Янв. 4, 2023

Язык: Английский

---

Substance P and Prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction

Brain Behavior and Immunity, Год журнала: 2022, Номер 108, С. 302 - 308

Опубликована: Дек. 19, 2022

Язык: Английский

---

Riechen und Riechstörungen

Laryngo-Rhino-Otologie, Год журнала: 2023, Номер 102(S 01), С. S67 - S92

Опубликована: Май 1, 2023

Zusammenfasssung Der Geruchssinn ist wichtig. Das wurde insbesondere v. a. Patient:innen mit infektbedingtem Riechverlust während der SARS-CoV2 Pandemie bewusst. Wir reagieren z. B. auf Körpergerüche unserer Mitmenschen – die Nase bestimmt/wen wir „riechen können“. warnt uns vor Gefahren, Wahrnehmung von Düften und Aromen beim Essen bedeuten Lebensqualität. Eine Anosmie muss daher ernst genommen werden. Obwohl sich olfaktorische Rezeptorneurone durch Regenerationsfähigkeit auszeichnen, sind Anosmien etwa 5% relativ häufig. Riechstörungen werden nach Ursache eingeteilt (z. Infekte, Schädelhirntraumen, chronische Rhinosinusitis, Alter) den daraus ergebenden unterschiedlichen Therapieoptionen Prognosen. gründliche Anamnese deshalb bedeutsam. Zur Diagnostik stehen verschiedenste Untersuchungsverfahren zur Verfügung, orientierenden Kurztests über ausführliche mehrdimensionale Testverfahren bis hin zu elektrophysiologischen bildgebenden Methoden. Damit quantitative gut erfassbar nachverfolgbar. Bei qualitativen wie Parosmie derzeit allerdings keine objektivierenden Diagnoseverfahren Verfügung. Die therapeutischen Möglichkeiten bei begrenzt. Trotzdem dem Riechtraining sowie verschiedenen additiven medikamentösen wirksame Optionen Von großer Bedeutung Beratung das kompetente Gespräch Patient:innen.

---

Comparison of prevalence and evolution of COVID-19 olfactory disorders in patients infected by D614 (wild) and B.1.1.7. Alpha variant: a brief report

European Archives of Oto-Rhino-Laryngology, Год журнала: 2023, Номер 280(7), С. 3461 - 3467

Опубликована: Март 21, 2023

Язык: Английский

---

Treatment of Olfactory Disorders After SARS – CoViD 2 Virus Infection

Ear Nose & Throat Journal, Год журнала: 2023, Номер 103(1_suppl), С. 48S - 53S

Опубликована: Март 28, 2023

The benefit of a nasal corticosteroid in the treatment persistent post-infectious smell disorders is not as clear previous studies assumed for olfactory training. This study would therefore like to describe strategies using example dysfunction result proven infection with SARS-CoViD-2-virus.

Язык: Английский

---

Olfactory recovery following omicron variant infection: a psychophysical prospective case–control study with six-month follow up

The Journal of Laryngology & Otology, Год журнала: 2023, Номер 137(12), С. 1395 - 1400

Опубликована: Май 17, 2023

This study aimed to evaluate the recovery of olfactory function at six months in individuals infected with coronavirus disease 2019 omicron variant, using psychophysical tests.A prospective case-control that included severe acute respiratory syndrome coronavirus-2 patients February and March 2022 was conducted. Patients underwent Sniffin' Sticks test within 10 days infection again after least 6 months. The scores were compared those a control group.In all, 102 120 controls enrolled study. At baseline, 26 (25.5 per cent) self-reported smell loss. median threshold, discrimination identification score 33.6 (interquartile range, 12.5) for cases 36.5 4.38) (p < 0.001). Based on scores, 12 34 reported dysfunction Eighty re-evaluation months; 37.1 4.75) no significant differences controls.Six infection, prevalence did not differ significantly from population.

Язык: Английский

---